Axcelis Technologies ACLS Deep Value Research

Hunting ten-year five-baggers among great growth stocks — pressing the upside question: "Can it get much bigger?"

• QHow large is its market ceiling? Is it expanding an existing pie, or creating an entirely new market?3/10

  A

  Baillie Gifford view upfront: the ceiling is medium-low. Against LTGG's yardstick of “5x in ten years,” ACLS almost certainly does not qualify. It is not creating an entirely new market; it is taking share within an existing and quite narrow process niche, rising and falling with the fab capex cycle. To explain this clearly, the ceiling has to be split into two layers: one is the long-term growth of broad semiconductor equipment, or WFE, which is indeed large and attractive; the other is the ion implantation subsegment, which is the ceiling ACLS can actually reach, and it is visibly much lower.

  Layer one, expanding an existing pie: high, but not ACLS's alone. AI data centers, advanced logic, memory, and “self-sufficiency” fab construction across regions are indeed making the equipment pie larger. SEMI expects global 300mm fab equipment spending to grow 18% in 2026 to $133 billion, then another 14% in 2027 to $151 billion, and expects it to keep climbing to $155 billion and $172 billion in 2028–2029. That is a genuine long-term tailwind. But note: this is the ceiling for all of WFE. Etch, deposition, metrology and inspection, and lithography all share in it. Ion implantation is only one process step, and not the fattest or most irreplaceable profit pool. ACLS benefits from this layer of growth, but it does not “define” it.

  Layer two, ACLS's real ceiling: narrow. Ion implantation is a structurally small niche. Most third-party estimates put the 2025 global ion implanter market at about $3 billion–$3.8 billion, with a CAGR of about 12%. In other words, the whole lane is roughly only 2%–3% of total WFE, which is on a hundred-billion-dollar scale. Within such a narrow market, ACLS and Applied Materials are the only two vendors with full ion implantation product lines, alongside Japan's Sumitomo, Nissin, and others; the leading players together already hold more than 60% share. Put differently, ACLS grows by continuing to take share in a narrow market that is already formed and where it is already one of the leaders, not by opening up an untouched frontier. That is the opposite of the story Baillie Gifford tends to favor, where a new category moves from 1% penetration toward 50%. The report itself also frames it as “a good company in a narrow lane within a good industry,” gives industry attractiveness 3/5, and explicitly notes that ion implantation “is not the fattest or most irreplaceable part of the profit pool.”

  The only factor that can lift this slightly toward “medium” is the relatively incremental power/SiC pie. This is the part of the ACLS narrative closest to “growth”: in 2025, power device applications represented 55% of its systems shipment value, and there were still 4 Purion evaluation tools at key customer sites. But the honest view is: first, this is still an extension of an existing market, power semiconductor manufacturing, not newly created demand from nowhere; second, since 2024, SiC has gone through visible inventory digestion and slower capacity expansion in EV and industrial end markets. It is both ACLS's growth option and a risk point for cyclical giveback. The report notes that 2025 revenue fell from $1.018 billion in 2024 to $839 million, a year-over-year decline, and that 2026Q1 operating margin was only 4.0%. Overall, under the Baillie Gifford framework I rate the ceiling as medium-low: the pie is getting larger, but ACLS gets only a narrow slice, that slice fluctuates with the capex cycle, and it lacks the nonlinear volume runway of a long penetration slope. This is a respectable good business in a narrow lane, but it is not the kind of ten-year 5x candidate LTGG seeks, where the market ceiling is so high it is hard to see the top.

  Jun 4, 2026
• QCan its revenue at least double over the next five years? Will growth be driven mainly by volume, price, or new businesses?3/10

  A

  Conclusion first: looking only at ACLS's legacy standalone business, an “organic doubling” over the next five years is a low-probability outcome. It is a high bar, not the base case. What could really make reported revenue jump in a “doubling-like” way is Veeco consolidation, but that is an expansion of the accounting boundary, not proof that this business itself has doubled in size. On growth drivers, volume, meaning the fab capex cycle plus power/SiC/memory ramp, is the main axis; price is only a supporting factor from “limited pricing power”; new business through M&A is a separate matter and must be accounted for separately.

  Start with the math. 2025 revenue was $839 million, and it was down year over year from $1.018 billion in 2024, according to the report's financial table. Organic doubling means reaching about $1.7 billion within five years, requiring roughly a 15% five-year CAGR. For a highly cyclical equipment stock that has just come down from a high point and posted only a 4.0% operating margin in 2026Q1, that is a steep slope. A more direct counterpoint comes from the company itself: management's 2026 full-year guidance is roughly flat with 2025, because memory recovery is expected to be offset by continued digestion in power and mature-node capacity. In other words, the first year of the five-year window is likely to go nowhere, leaving the entire doubling task to the following four years. That alone shows that “organic doubling” is not the natural result of a cyclical upturn; it requires a strong upcycle to become reachable. The report's DCF also assumes only 7% growth in the neutral case over the first ten years and 10% in the optimistic case, both below the ~15% needed for doubling, consistent with the view that organic doubling is a high bar.

  Split growth into volume, price, and new business, then assess each realistically. Volume is the main driver: the long-term backdrop is not bad. SEMI expects global 300mm fab equipment spending to rise 18% in 2026 to $133 billion and 14% in 2027 to $151 billion, with AI, advanced logic, memory, and regionalized fab construction all supporting equipment demand. But ion implantation is only a narrow link in broad WFE. ACLS captures “industry volume × its share of one small segment,” and the mix is shifting. The growth engine of recent years, power devices/SiC, which accounted for 55% of systems shipment value in 2025, is currently in a capacity digestion phase, with EV and SiC softness in the near term, while the baton is moving toward DRAM/HBM. ACLS has high share in SiC implantation, and the transition from 6-inch to 8-inch wafers is a multi-year tailwind, but “evaluation tools converting to volume production” and “memory recovery materializing” still need proof. If timing disappoints, volume elasticity does not come back. Price is secondary: the report is clear that the company has only “limited pricing power.” From 2021–2025, gross margin stayed around 43%–45% because of product mix and technology upgrades, not because the company could raise prices at will. In 2026Q1, gross margin instead fell to 40.5%, and service gross margin turned negative, so price cannot realistically carry a doubling. New business through M&A is another ledger: once the all-stock Veeco deal is consolidated, with an exchange ratio of 0.3575, ACLS shareholders owning about 58.4% of the combined company, only China SAMR approval remaining, and closing expected in the second half of 2026, combined revenue will show a step change. But that is putting another company inside the boundary, not ACLS's legacy business doubling by itself. Veeco's core business is not ion implantation, and synergies and integration remain unproven, so it must be kept strictly separate from organic growth.

  The clear Baillie Gifford view. Baillie Gifford wants “organic growth that compounds on its own and can become 5x over ten years.” On that yardstick, ACLS does not support a five-year organic doubling. It is a highly cyclical, narrow-moat equipment company whose revenue swings with customer capex rather than accumulating like a subscription model. Even the sell-side average price target of $128 is below the current ~$155, implying the market sees recovery as a 2027–2028 event rather than a validated high-growth curve. The honest framing is: on the organic side, reaching ~$1.7 billion requires a strong upcycle plus both SiC and memory execution, an optimistic case rather than the base case; on the reported side, Veeco consolidation can create a “doubling-like” revenue number, but that means the boundary got larger, not that the business got better. Confusing the two is exactly where this stock can be most easily overvalued.

  Jun 4, 2026
• QWhat is its core competitive advantage? Will this moat widen or narrow over the next three to five years?4/10

  A

  One-sentence conclusion: the core advantage is “a duopoly position in ion implantation alongside Applied Materials + decades of process know-how + switching costs from customer production qualification + aftermarket stickiness from the installed base.” But by Baillie Gifford's standard of whether the moat can keep widening, it is more like a narrow moat that is “stable overall, widening locally in SiC, and not decisively advantaged in broad competition.” That deserves a medium-weak judgment, not the kind of great moat that can widen for ten years.

  The core competitive advantage has four layers. The hardest layer is market structure: in ion implantation systems, ACLS and Applied Materials are the only two vendors with full product lines, covering high current, medium current, and high energy, with Japan's Sumitomo/Nissin, Taiwan's AIBT, and Chinese domestic players covering parts of the market. But honestly, “duopoly” does not mean “50/50.” Third-party data show AMAT at a little over 60% share in ion implantation and ACLS at about 20%. ACLS is clearly number two, not a co-equal leader. The second layer is process know-how and customer qualification: ion implantation is the critical step of precisely injecting dopants into wafers. Once equipment enters volume production, switching suppliers requires process requalification and a bet on line yield, so switching costs are real. That is also why the report says it stayed profitable through the weak 2020–2025 cycle. The third and fourth layers are aftermarket from the installed base, including spares, upgrades, maintenance, and service, plus global service responsiveness. The report rates this moat as “present but not wide, with strength 3/5,” and I agree: it rests on focused specialist capability, not brand premium, network effects, or crushing scale.

  Direction over the next three to five years: locally widening, overall uncertain. The disagreement itself is the answer. The part that is genuinely widening is power devices/SiC: ACLS's share in SiC ion implantation is as high as 70%–80%, and it continued to reinforce that position with the Purion Power Series+ launch in September 2025 and Purion H6 in February 2026. The report also notes that power applications accounted for 55% of systems shipment value in 2025 and that evaluation tools remained at key customer sites. In this branch, the moat is indeed widening. But I would not say the main river of “broad ion implantation” is widening, for three reasons: ① AMAT is not a weak rival that can be easily overtaken, and it has stronger cross-cycle capacity in fatter etch/deposition profit pools; ② export controls relatively benefit non-U.S. competitors and Chinese domestic substitution, and new searches show local players such as Xinyu Semiconductor filling gaps; ③ ACLS customers are highly concentrated in China-sensitive regions, with the top 10 customers accounting for 72.9% of revenue in 2026Q1. If policy changes, the moat can be “routed around” rather than directly breached.

  An honest Baillie Gifford score. LTGG wants a moat that “widens over ten years before the market realizes it.” ACLS is not quite that. Its pricing power is limited pricing power: in most years, gross margin held at 43%–45%, but it had fallen to 40.5% by 2026Q1 and service gross margin even turned negative, proving it cannot simply raise prices at will. This moat is therefore more like “defensible, but risky to extrapolate in one direction.” The SiC tributary is genuinely improving, but if power/SiC conditions cool or evaluation tools convert to production more slowly than expected, the previous growth premium can unwind quickly. The conclusion stays aligned with the report: moat strength 3/5, direction stable overall rather than broadly expanding. On Baillie Gifford's question of “can it keep widening,” the answer is medium-weak. The whole case rests on whether the single SiC branch can convert to volume production, not on a wide river that naturally compounds wider.

  Jun 4, 2026
• QIf its core business is disrupted, does it have the DNA to reinvent itself? How does it handle mistakes and bad news?4/10

  A

  Conclusion first: from a Baillie Gifford perspective, ACLS has weak “reinvention DNA,” while its “honest culture in handling bad news” can be rated medium. It has several real positive signals: it did not cut R&D in a weak cycle and instead increased it, it proactively positioned in power/SiC, and bad news was found and disclosed by the company itself. But these look more like “a decent cyclical equipment company doing the right things” than the kind of great growth company Baillie Gifford seeks, one that can remake its entire fate after the core business is disrupted. Separate the two questions: reinvention DNA and honest culture.

  Reinvention DNA: weak. The extreme case behind this Baillie Gifford question is: “If the core business is disrupted, can you find another life?” ACLS's actual profile is that 98.2% of 2025 revenue came from the single ion implantation process. It has no history of “the core business being disrupted and the company being reborn through a second curve.” It remains, in essence, a highly cyclical, narrow-moat, single-process equipment company. The “reinvention” evidence it can offer is product repositioning within the existing lane toward the higher-growth power device/SiC direction. In September 2025, the company launched the Purion Power Series+ platform for SiC and superjunction power devices, and the report notes that power applications already accounted for 55% of that year's system shipment value, with evaluation tools still at key customer sites. This is a sensible move to capture industry beta and deserves credit; but it is “changing the application within the same process,” not “building a new platform after the core is disrupted.” If ion implantation itself were truly replaced, for example by a mature doping process that did not require implantation, ACLS has not shown a second leg. By Baillie Gifford's standard, it does not have the disruptive reinvention DNA of a great growth company.

  Not cutting R&D in a weak cycle is the part of this business that most resembles long-termism. Under the report's figures, R&D was about 8.5%–10.4% of revenue from 2021–2024 and rose to about 13% in 2025. I checked this online: in 2025, quarterly R&D intensity was roughly in the 11.5%–14.1% range (Q1≈14.1%, Q2≈13.9%, Q3≈11.5%). Revenue stepped down and margin fell to single digits, yet R&D intensity was lifted. This choice, “do not self-harm in adversity; preserve the technology path,” is a cultural trait Baillie Gifford would appreciate. But honestly, for an equipment company without a wide moat, higher R&D is more of a defensive necessity forced by competition, with AMAT present and Chinese domestic substitutes rising, than a proactive bet on a new species. It should not be overweighted.

  Honest culture: medium. Transparency and an internal-control blemish are two sides of the same event. The clearest evidence of “how it handles bad news” is the backlog incident. I verified the details: during preparation of the third-quarter 2024 statements, it was the company's own internal finance team that found a backlog calculation error. The error came from double-counting prepayments on certain system orders, and spanned from 2019 through 2024Q2. The company proactively disclosed the corrected historical figures, with corrected backlog at $879 million as of 2024/6/30 versus the previously reported $994 million, a difference of -$115 million. The transparent side: it was self-identified, self-corrected, and proactively disclosed, not exposed by regulators or short sellers, which is respectable for a mid-cap technology company. The questionable side: an operating metric was wrong for five years before being discovered, showing that execution of internal controls around operating indicators was not perfect. The report is right to call it a “yellow light” requiring ongoing monitoring. Put together, I rate honesty as medium rather than strong: the company is willing to admit mistakes, but it has not proven the ability to avoid this kind of mistake.

  A current variable that increases uncertainty: the CFO transition. In March 2026, David Ryzhik became Interim CFO and James Coogan departed. Objectively, based on disclosure, Coogan left to become CFO of a public company in another industry; the company explicitly said the departure was unrelated to financial reporting or policy disagreements. Ryzhik already led IR and corporate strategy and was deeply involved in Veeco integration planning, so this alone is not a danger signal. But the timing is sensitive: it happened during the Veeco all-stock deal process, still awaiting China SAMR approval, with ACLS shareholders set to own about 58.4% of the combined company. Changing the finance lead before consolidation raises execution uncertainty. Its link to “reinvention/honesty” is this: a company that wants to expand its boundary through M&A and change its own profile needs continuity and credibility in the finance function, and that role is currently interim.

  One-sentence Baillie Gifford summary: ACLS is a decent company that does the right things: it protects R&D in adversity, proactively pursues power/SiC, and self-identifies and corrects bad news. But it has neither a history of reinvention after disruption nor a second curve, and its honest culture comes with a five-year internal-control flaw. Against Baillie Gifford's “great growth stock that can become 5x in ten years” yardstick, reinvention DNA is weak and honest culture is medium. That fits the report's “Watch, good company but not a wide moat” framing, and the positives should not lead us to treat it as a growth company with destiny-changing DNA.

  Jun 4, 2026
• QDoes management, especially the founder, have a long-term view and deep alignment with the company? Is it willing to sacrifice current profit for five to ten years out?4/10

  A

  Conclusion first: on Baillie Gifford's “founder alignment” dimension, ACLS rates medium-low. It is not founder-led; a professional management team runs the company. Management alignment is “medium” in scale, based on systems and professional discipline rather than “all-in personal wealth.” There is real positive evidence of long-term thinking, including not cutting R&D in a weak cycle, continued buybacks, and a strong balance sheet. But there are also two clear uncertainties: buybacks may not all have been done in undervalued territory, and the Veeco deal has not yet proven value creation. For a highly cyclical, narrow-moat equipment stock rated “Watch,” this dimension cannot support the Baillie Gifford LTGG narrative of “a founder willing to sacrifice today for ten years out.”

  Start with the most important point: this is not a founder-led company. Current CEO Russell Low has a background at Varian, Applied Materials, and Veeco. He is a classic industry professional manager, not a founder whose life savings and reputation are tied to the company. The kind of businesses Baillie Gifford LTGG tends to favor, with a founder at the helm for the long term, a ten-year horizon, and deep alignment with the company, do not match ACLS's governance structure. This has to be made clear first, because it means ACLS cannot be held on a “trust the founder” logic. The logic has to be “trust the system + trust the cycle + trust the price.”

  Alignment: medium, not “very strong.” As of 2026-03-12, CEO Russell Low held 51,290 shares, and all current directors and executives together held 151,010 shares, according to the company's 2026 DEF 14A proxy statement. Using the current stock price of about $155–157 and market cap of about $4.8–$5.1 billion, the CEO's economic interest is not negligible, but in a company worth nearly $5 billion, overall management ownership is small. It is far from an owner-operator whose wealth is highly concentrated in the company's stock and who is in the same boat as minority shareholders. Put differently, buying ACLS means relying more on its institutional arrangements and professional discipline than on “the boss cannot afford to lose.” The good side is that governance is clean: the company has stock ownership guidelines, a clawback policy, insider trading restrictions, no single-trigger golden parachutes, and no executive perquisites. These are better than many mid-cap technology companies. But “proper governance” and the “deep founder alignment” Baillie Gifford seeks are two different things. The former is a baseline; the latter is a source of extra credit. ACLS has the former and lacks the latter.

  Long-term view: real positives, but equally real doubts. On the positive side, management has shown behavior consistent with “willingness to sacrifice current profit for the long term.” In 2025, as the industry weakened and profit stepped down materially, R&D expense as a share of revenue rose rather than fell, from the report's 8.5%–10.4% range in 2021–2024 to about 13% in 2025. It did not cut technical investment to protect short-term EPS, which is exactly the orientation Baillie Gifford likes to see. It also had almost no interest-bearing debt, maintained a strong balance sheet, with cash and investments of about $570 million in 2026Q1, and continued buybacks, with $100 million authorized in 2022, another $200 million added in 2023, another $100 million added in 2025, and about $110 million still remaining as of 2026-03-31. The doubts are also substantial: first, “buybacks did reduce share count” does not mean “they were all done below intrinsic value.” Looking back from today's not-cheap valuation, having buybacks cannot be mechanically counted as “high-quality capital allocation.” Second, the all-stock Veeco acquisition, with each Veeco share exchanged for 0.3575 ACLS share and ACLS shareholders owning about 58.4% of the combined company, changes the company's boundary, still awaits China SAMR approval, and has not yet proven synergies. Add the March 2026 CFO transition, with James Coogan leaving and David Ryzhik becoming interim CFO, and execution uncertainty rises during the acquisition process. These factors keep “long-term view” from earning full marks.

  One-sentence Baillie Gifford framing: ACLS's management is a good team: professional, disciplined, not prone to wasteful spending, and willing to invest in R&D through a weak cycle. But it is not the kind of Baillie Gifford LTGG company where a founder has put personal wealth on the line and willingly sacrifices the present for five to ten years out. On “founder alignment,” the honest score is medium-low: it passes on systems and discipline, and loses points for the lack of founder-level deep alignment plus unresolved uncertainty around buyback pricing and acquisition value.

  Jun 4, 2026
• QIf it disappeared tomorrow, how much would customers miss it? Is its growth model sustainable and not dependent on harming society or regulation?5/10

  A

  Conclusion first: indispensability is “fairly strong,” but the social sustainability dimension is closer to “medium-weak.” The growth itself is not socially harmful, but its demand base is heavily tied to the China market and the geopolitical policy red line of U.S. export controls, a real and persistent regulatory vulnerability. Overall, under the Baillie Gifford framework, I rate this dimension medium, with indispensability adding points and regulatory sustainability subtracting them.

  If it disappeared tomorrow, how much would customers miss it? They would, but not in an “irreplaceable” way. Ion implantation is an unavoidable key process in chipmaking: by precisely implanting dopant ions into the silicon lattice to control conductivity and form p-n junctions, it is an indispensable step in modern semiconductor doping, superior to older diffusion processes in precision, depth, and uniformity. Without it, chips cannot be made. Globally, the only vendors that can provide full ion implantation product lines are ACLS and Applied Materials. Once equipment enters volume production, switching means process requalification and yield ramp again, so customers do not change suppliers lightly. This is the “narrow but real” moat described in the report. But “miss it” needs a discount: ACLS is not the only supplier. In 2024, AMAT held about 62% of ion implantation and ACLS about 21%. If major logic/memory customers truly needed to switch, AMAT could absorb the work. The more precise statement is: in the narrow power device/SiC lane, ACLS is almost irreplaceable, with outside estimates putting ACLS's SiC ion implantation share at about 70%–80%, and it has launched the Purion Power Series+ platform designed for next-generation SiC. In broad ion implantation, however, it is “painful but replaceable.” Customer concentration also confirms stickiness: in 2025, one customer accounted for 11% of revenue, and in 2026Q1, four customers accounted for 14.6%/11.1%/10.7%/10.5% of receivables. This deep binding is evidence that customers would miss it, but also means losing one large customer hurts.

  Is the growth model sustainable? At the product level, it is positive, but the foundation of growth sits on a regulatory red line. Start with the good side: ACLS enables semiconductors, power devices, and SiC/GaN, ultimately serving real social needs such as new energy, EVs, and AI data centers, where HBM4 requires more complex implantation steps. It has no obvious social harm and does not profit by damaging users or society. That is clean and fits Baillie Gifford's requirement that growth should be socially useful. The real issue is the “not dependent on regulation” part: ACLS's demand base is highly tied to China. The company repeatedly flags the importance of China and Asian markets, as well as export-control risk. Asia, especially China, has historically represented more than 80% of systems revenue, and the exposure is volatile. China fell to 32% of total revenue in 2025Q4 from 46% in the prior quarter. In other words, its growth model is partly tied to the mood of geopolitics: tighter U.S. controls on advanced semiconductor equipment to China, or Chinese domestic substitution, can directly remove part of demand. This is not “growth by harming society,” but it is “growth that is not independent and sits on a regulatory vulnerability,” exactly what this Baillie Gifford question is meant to flag.

  The Baillie Gifford landing point. LTGG seeks great growth companies that can become 5x in ten years, are indispensable, and can grow cleanly. ACLS earns partial credit on “indispensability”: critical process + duopoly + high switching costs, but not exclusive. On “social sustainability of growth,” it is a mixed case: the product is harmless and useful, while the demand foundation carries regulatory risk. The downstream use cases are respectable, but the base of demand is tied to a U.S.-China policy line the company cannot control. Put together, this dimension is not really a source of extra credit under the Baillie Gifford framework; it is closer to “qualified but fragile”. Customers would genuinely miss it if it disappeared, especially SiC customers, but whether it can keep growing depends to a large degree not on how good the company is, but on the path of export controls. This matches the report's “Watch” rating and its treatment of “China and export controls” as one of the three core uncertainties.

  Jun 4, 2026
• QWhat are the unit economics of this business, such as gross margin and incremental returns? Do they improve or deteriorate as scale increases? Where does the earned cash go?4/10

  A

  Conclusion first: ACLS's unit economics are “medium-high, but not excellent.” Gross margin is moderate, incremental returns are dominated by strong operating leverage, improving in upcycles and quickly worsening in downcycles rather than monotonically improving with scale, and ROIC is clearly below equipment leaders. The cash goes into buybacks, R&D, and M&A. The direction is not disorderly, but whether it is “spent well” has not yet been proven. On Baillie Gifford's question of whether unit economics are excellent and improve with scale, my judgment is mixed and slightly neutral.

  Unit economics: moderate gross margin, incremental returns swing hard with the cycle. In ion implantation equipment, gross margin stayed around 43%–45% from 2021–2025, then fell in 2026Q1 to GAAP 40.5%, with service gross margin even turning negative. That is a “not weak, but not top-tier” position. The horizontal anchor makes this clear: over the same period, Applied Materials had gross margin around 48%, Lam Research around 50%, and KLA stayed above 60%. The more important evidence is incremental return: operating margin was about 23% in the strong 2022 cycle, fell to 14.2% in 2025, and was only 4.0% in 2026Q1. That line tells Baillie Gifford the key point: this business has strong operating leverage, but the leverage cuts both ways. When the cycle is strong and revenue expands, fixed R&D and manufacturing costs are spread out, and a large share of incremental gross profit drops to operating profit, making unit economics look very attractive. Once inventory digestion and customer pushouts hit, as they are now, the same leverage reverses, margins fall sharply, and the service line can even lose money. So it does not meet Baillie Gifford's favored pattern of “unit economics monotonically improving after scale”. Whether they improve or deteriorate is driven mainly by cycle position, not by scale itself.

  Capital returns: respectable, but a tier below the leaders. ACLS has ROE around 9.7%–11.7%, ROIC around 11.5%, and ROA around 4.5%–6.3%, all down from the cyclical peak. These returns are not bad in isolation, but they look ordinary within equipment. AMAT's five-year average ROIC is about 46%, KLA has long stayed above 30%, and LRCX is also around 40%. In other words, for the same dollar reinvested, the leaders can extract far higher returns than ACLS. For Baillie Gifford, which is looking for “5x in ten years,” incremental capital return is the compounding engine. ACLS is a mid-tier player on that engine, not a scarce company that becomes increasingly efficient at reinvesting as it grows.

  Where the cash goes: buybacks + R&D + M&A, with the direction right and effectiveness unproven. None of the three uses looks like reckless spending. First is buybacks: $100 million authorized in 2022, another $200 million in 2023, another $100 million in 2025, and about $110 million still remaining as of 2026Q1. But honestly, buybacks may not all have occurred in undervalued territory; the current valuation, with TTM PE around 41x, is not cheap, so “there are buybacks” cannot be mechanically equated with “excellent capital allocation.” Second is R&D: in 2025, R&D rose countercyclically to about 13% of revenue. Not cutting technical investment when the industry weakens is the right long-term choice and is part of why it can defend gross margin. Third is the Veeco acquisition, all-stock, intended to expand the boundary from pure ion implantation into a broader equipment platform. But the deal still awaits Chinese regulatory approval, synergies have not yet been realized, and whether it creates value or “trades dilution for scale” cannot be concluded today.

  One sentence for Baillie Gifford: this is a business with respectable but not excellent unit economics, and economics that do not automatically improve with scale. Gross margin is moderate, incremental returns are driven by cyclical leverage, and ROIC trails the leaders. The money is going in the right broad directions, buybacks/R&D/M&A, but whether it is being spent well will only be tested after the acquisition closes and the next cycle arrives. Against Baillie Gifford's yardstick of “excellent unit economics + continuous improvement with scale,” ACLS cannot provide a clear affirmative answer, which is consistent with the report's “Watch” rating.

  Jun 4, 2026
• QWhat conditions need to hold simultaneously for it to rise 5x in ten years? Are those conditions realistic? What expectations are embedded in today's share price?2/10

  A

  Direct judgment: from a Baillie Gifford perspective, the probability of ACLS rising “5x in ten years” is low. It requires a long list of conditions to materialize almost simultaneously, while today's roughly $157 share price has already prepaid “cycle recovery + Veeco acquisition synergies.” The Baillie Gifford LTGG yardstick is 5x in ten years, or a quintuple. In scale terms, that means a current market cap of about $4.8–$5.1 billion would have to become about $24–$26 billion ten years from now. For a narrow-lane cyclical equipment company with only $839 million of 2025 revenue, about $100 million of TTM net income, and operating margin that has just fallen from a high level to 14%, with only 4% in 2026Q1, this is not a destination that “business as usual compounding” can reach. It requires revenue and profit to grow rapidly for a long time while valuation does not compress materially. These two requirements are themselves in tension: today's TTM PE is already ~41x, and the higher the starting point, the harder it is to assume the multiple will still be equally high ten years from now.

  The required conditions, assessed one by one, are mostly questionable:

  • Power devices / SiC must truly scale and support a second curve. This is the most plausible item. In 2025, power applications already represented 55% of systems shipment value, and there were still 4 Purion evaluation tools at key customer sites. But SiC is currently in inventory digestion and price competition. The pace of evaluation-to-production conversion and customer capex remains uncertain. The report also states plainly that if conditions cool or conversion to volume production disappoints, the growth premium will unwind. The opportunity is real, but far from certain.
  • The Veeco all-stock acquisition must truly create value, not dilute it. The deal still awaits China SAMR approval, and integration has never been tested. ACLS shareholders will own about 58.4% after the merger. A 5x outcome requires the acquisition to deliver incremental profit where 1+1>2, not dilute per-share value. That is a pure unknown.
  • Operating margin must return to the mid-to-high teens and stay there for a long time. Even the report's optimistic case only assumes this level, while the current figure is 4%. For a 5x outcome, recovery alone is not enough; the company must sustain high margins on a larger base.
  • Permanent share loss from China / export controls must be avoided. The company repeatedly flags the importance of China and export-control risk. Domestic and non-U.S. competitors may benefit under controls. This is a structural headwind, not something the company fully controls.
  • The valuation must remain high for ten years. Even if profit grows several times, if PE normalizes from 41x toward a more ordinary capital equipment multiple of 20–25x, the 5x return is heavily impaired. A 5x outcome almost requires “profit rises sharply + valuation does not shrink,” a low-probability combination.

  What today's share price implies: recovery and synergies have already been prepaid, leaving very little room for “5x.” The report's neutral DCF intrinsic value is only about $79, and the neutral long-term annualized return from buying at the current price is only 7–8%, with conservative at 5–6% and optimistic only 9–10%. FCF yield is about 2.19%. These figures describe a “reasonable-to-expensive, modest return” path, not a 5x path, since 5x in ten years requires roughly 17–18% annualized. Market sentiment is indeed warm, with B. Riley raising its target price to $180 in 2026-05, but that is a one-year target implying roughly one to two tens of percent upside, not the same order of magnitude as Baillie Gifford's “5x in ten years.” The conclusion is blunt: ACLS can still rise, but “5x in ten years” requires power/SiC to scale sharply, the acquisition to succeed, margins to keep recovering, share not to be lost, and valuation not to compress. Too many things must go right at the same time, and any broken link breaks the chain. Under the Baillie Gifford framework, this is a low-probability “5x” bet with no margin of safety at the current price, better placed on a watchlist until a cheaper price appears or post-acquisition cash flow proves itself, rather than bought today under LTGG standards.

  Jun 4, 2026
• QWhy has the market not realized all this yet? Is it too hard to understand, too overlooked, or too long-term? What would become the “narrative inflection point”?3/10

  A

  Conclusion first: this question is a negative for ACLS. The premise behind this Baillie Gifford question, “a great growth stock is being systematically undervalued by the market,” mostly does not apply to ACLS. It is not a hidden growth stock that has not been seen. Quite the opposite: the share price has risen about 175% over the past 52 weeks, TTM PE is in the 41x–49x range, FCF yield is only about 1.8%–2.2%, and B. Riley upgraded the rating to “Buy” in May 2026 and raised its target price from $150 to $180. The market has not only noticed it; it may already have priced in, or even overpaid for, the optimistic narrative of “cycle recovery + Veeco synergies + power/SiC ramp”. The honest answer is not “too hard to understand / too overlooked / too long-term,” but “the market understands it clearly, and may be too optimistic.”

  If there is an “expectations gap,” it is more likely downward than upward. The Baillie Gifford model is good at finding cases where the market underestimates the long-term ceiling. For ACLS today, the more realistic risk is the reverse: the market is treating cyclical peak conditions as normal. In the report, operating margin slid from 23.5% in 2023 to 4.0% in 2026Q1, gross margin fell below 42%, and elevated inventory of $326 million has not yet been fully digested, yet the valuation multiple remains above 40x. In other words, if a “perception gap” exists here, it looks more like the market underreacting to a step-down in normalized earnings than underreacting to growth potential. That is exactly why the report rates it “Watch” rather than “Buy”: the current price prepays too much recovery and acquisition value, lacks a margin of safety, and the neutral case annualized return is only 7%–8%.

  The so-called “narrative inflection point” is two-way, and the downside side is not obscure. The upside inflection points are real and clear: the Veeco all-stock acquisition closing, currently mainly waiting for China SAMR approval and expected in the second half of 2026; power/SiC evaluation tools converting smoothly to volume production; and margin returning to the mid-to-high teens after excluding acquisition costs. Any of these could “fill in” the earnings behind the current high valuation. But the downside inflection points are just as concrete: a prolonged weak cycle, gross margin staying below 42%, inventory remaining elevated, China share being lost under export controls, or acquisition integration damaging ROIC. The key point is that the upside inflection points are largely already being priced by the market, which is the source of PE 41x+ and sell-side target upgrades, while if a downside inflection happens, it hits both valuation and earnings. The report's warning of a 40%–60% permanent capital loss tail risk is therefore not exaggerated.

  One-sentence Baillie Gifford close: It is a mismatch to force ACLS into the image of a “great growth stock overlooked by the market.” It is a respectable equipment company, but with a narrow moat, high cyclicality, and a valuation that already carries a premium. The market has not ignored it; it has given it plenty of optimistic expectations. For a Baillie Gifford-style long-term growth investor, the real question is not “why has the market not realized it yet,” but “when the market has already priced the best script, how much margin of safety remains if I buy today.” The report's answer is: not much.

  Jun 4, 2026